186 related articles for article (PubMed ID: 38426229)
21. [Radiotherapy for local disease in metastatic prostate cancer.].
Cambeiro M; Calvo FA
Arch Esp Urol; 2018 Mar; 71(3):298-305. PubMed ID: 29633951
[TBL] [Abstract][Full Text] [Related]
22. Efficacy of Systemic Treatment in Prostate Cancer Patients With Visceral Metastasis: A Systematic Review, Meta-analysis, and Network Meta-analysis.
Yanagisawa T; Rajwa P; Kawada T; Mori K; Fukuokaya W; Petrov P; Quhal F; Laukhtina E; von Deimling M; Bianchi A; Majdoub M; Pradere B; Kramer G; Kimura T; Shariat SF
J Urol; 2023 Sep; 210(3):416-429. PubMed ID: 37339479
[TBL] [Abstract][Full Text] [Related]
23. Metastasis-directed therapy of regional and distant recurrences after curative treatment of prostate cancer: a systematic review of the literature.
Ost P; Bossi A; Decaestecker K; De Meerleer G; Giannarini G; Karnes RJ; Roach M; Briganti A
Eur Urol; 2015 May; 67(5):852-63. PubMed ID: 25240974
[TBL] [Abstract][Full Text] [Related]
24. Triplet therapy with androgen deprivation, docetaxel, and androgen receptor signalling inhibitors in metastatic castration-sensitive prostate cancer: A meta-analysis.
Ciccarese C; Iacovelli R; Sternberg CN; Gillessen S; Tortora G; Fizazi K
Eur J Cancer; 2022 Sep; 173():276-284. PubMed ID: 35964470
[TBL] [Abstract][Full Text] [Related]
25. The Efficacy of Enzalutamide plus Androgen Deprivation Therapy in Oligometastatic Hormone-sensitive Prostate Cancer: A Post Hoc Analysis of ARCHES.
Armstrong AJ; Iguchi T; Azad AA; Villers A; Alekseev B; Petrylak DP; Szmulewitz RZ; Alcaraz A; Shore ND; Holzbeierlein J; Gomez-Veiga F; Rosbrook B; Zohren F; Haas GP; Gourgiotti G; El-Chaar N; Stenzl A
Eur Urol; 2023 Aug; 84(2):229-241. PubMed ID: 37179240
[TBL] [Abstract][Full Text] [Related]
26. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.
Heidenreich A; Bastian PJ; Bellmunt J; Bolla M; Joniau S; van der Kwast T; Mason M; Matveev V; Wiegel T; Zattoni F; Mottet N;
Eur Urol; 2014 Feb; 65(2):467-79. PubMed ID: 24321502
[TBL] [Abstract][Full Text] [Related]
27. Stereotactic body radiotherapy (SBRT) versus androgen deprivation therapy (ADT) for oligometastatic prostate cancer: protocol for a prospective randomised control clinical trial.
Zhao X; Wang T; Ye Y; Li J; Gao X; Zhang H
BMJ Open; 2022 Sep; 12(9):e051371. PubMed ID: 36180115
[TBL] [Abstract][Full Text] [Related]
28. The cytoreductive radical prostatectomy in metastatic prostate cancer.
Vladimír Š; Zuzana S; Hana Š
Klin Onkol; 2022; 35(1):55-62. PubMed ID: 35236082
[TBL] [Abstract][Full Text] [Related]
29. Lutetium-177-PSMA-I&T as metastases directed therapy in oligometastatic hormone sensitive prostate cancer, a randomized controlled trial.
Privé BM; Janssen MJR; van Oort IM; Muselaers CHJ; Jonker MA; de Groot M; Mehra N; Verzijlbergen JF; Scheenen TWJ; Zámecnik P; Barentsz JO; Gotthardt M; Noordzij W; Vogel WV; Bergman AM; van der Poel HG; Vis AN; Oprea-Lager DE; Gerritsen WR; Witjes JA; Nagarajah J
BMC Cancer; 2020 Sep; 20(1):884. PubMed ID: 32928177
[TBL] [Abstract][Full Text] [Related]
30. Adding abiraterone to androgen deprivation therapy in men with metastatic hormone-sensitive prostate cancer: A systematic review and meta-analysis.
Rydzewska LHM; Burdett S; Vale CL; Clarke NW; Fizazi K; Kheoh T; Mason MD; Miladinovic B; James ND; Parmar MKB; Spears MR; Sweeney CJ; Sydes MR; Tran N; Tierney JF;
Eur J Cancer; 2017 Oct; 84():88-101. PubMed ID: 28800492
[TBL] [Abstract][Full Text] [Related]
31. Extended Results and Independent Validation of a Phase 2 Trial of Metastasis-Directed Therapy for Molecularly Defined Oligometastatic Prostate Cancer.
Glicksman RM; Ramotar M; Metser U; Chung PW; Liu Z; Vines D; Finelli A; Hamilton R; Fleshner NE; Perlis N; Zlotta AR; Bayley A; Helou J; Raman S; Kulkarni G; Catton C; Lam T; Chan R; Warde P; Gospodarowicz M; Jaffray DA; Berlin A
Int J Radiat Oncol Biol Phys; 2022 Nov; 114(4):693-704. PubMed ID: 36031465
[TBL] [Abstract][Full Text] [Related]
32. [Metachronous oligometastatic prostate cancer-the more the better or only local treatment?].
Steuber T; Maurer T; Miller K
Urologe A; 2021 Dec; 60(12):1534-1545. PubMed ID: 34734294
[TBL] [Abstract][Full Text] [Related]
33. Oligorecurrent prostate cancer treated with metastases-directed therapy or standard of care: a single-center experience.
Boeri L; Sharma V; Kwon E; Stish BJ; Davis BJ; Karnes RJ
Prostate Cancer Prostatic Dis; 2021 Jun; 24(2):514-523. PubMed ID: 33268854
[TBL] [Abstract][Full Text] [Related]
34. Intensification of Systemic Therapy in Addition to Definitive Local Treatment in Nonmetastatic Unfavourable Prostate Cancer: A Systematic Review and Meta-analysis.
Rajwa P; Pradere B; Gandaglia G; van den Bergh RCN; Tsaur I; Shim SR; Yanagisawa T; Laukhtina E; Mori K; Mostafaei H; Quhal F; Bryniarski P; Compérat E; Roubaud G; Massard C; Merseburger AS; Leapman MS; Spratt DE; Saad F; Joniau S; D'Amico AV; Briganti A; Shariat SF; Ploussard G;
Eur Urol; 2022 Jul; 82(1):82-96. PubMed ID: 35465985
[TBL] [Abstract][Full Text] [Related]
35. Taxane-based chemohormonal therapy for metastatic hormone-sensitive prostate cancer.
Sathianathen NJ; Philippou YA; Kuntz GM; Konety BR; Gupta S; Lamb AD; Dahm P
Cochrane Database Syst Rev; 2018 Oct; 10(10):CD012816. PubMed ID: 30320443
[TBL] [Abstract][Full Text] [Related]
36. Current evidence on local therapy in oligometastatic prostate cancer.
Basourakos SP; Henning G; Karnes RJ
Curr Opin Urol; 2024 May; 34(3):198-203. PubMed ID: 38305293
[TBL] [Abstract][Full Text] [Related]
37. Benefits of Using Stereotactic Body Radiotherapy in Patients With Metachronous Oligometastases of Hormone-Sensitive Prostate Cancer Detected by [18F]fluoromethylcholine PET/CT.
Bouman-Wammes EW; van Dodewaard-De Jong JM; Dahele M; Cysouw MCF; Hoekstra OS; van Moorselaar RJA; Piet MAH; Verberne HJ; Bins AD; Verheul HMW; Slotman BJ; Oprea-Lager DE; Van den Eertwegh AJM
Clin Genitourin Cancer; 2017 Oct; 15(5):e773-e782. PubMed ID: 28462855
[TBL] [Abstract][Full Text] [Related]
38. Safety and Efficacy Study of Neoadjuvant Radiohormonal Therapy for Oligometastatic Prostate Cancer: Protocol of an Open-Label, Dose-Escalation, Single-Centre Phase I/II Clinical Trial.
Zhao X; Xiao YT; Yang Y; Ye Y; Chang Y; Jiang L; Eftekhar M; Ren S; Zhang H
Cancer Control; 2022; 29():10732748221120462. PubMed ID: 35980734
[TBL] [Abstract][Full Text] [Related]
39. Management of Metastatic Hormone-Sensitive Prostate Cancer (mHSPC): an Evolving Treatment Paradigm.
Weiner AB; Nettey OS; Morgans AK
Curr Treat Options Oncol; 2019 Jul; 20(9):69. PubMed ID: 31286275
[TBL] [Abstract][Full Text] [Related]
40. [Treatment concepts for primary oligometastatic prostate cancer].
Knipper S; Graefen M; Hadaschik B; Wiegel T
Urologe A; 2020 Jun; 59(6):659-664. PubMed ID: 32274541
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]